Introduction
TGase 2 (EC2.1.2.13) is a crosslinking enzyme that has been implicated in numerous cellular pathways, including cancer cell proliferation, migration, angiogenesis, epithelial mesenchymal transition and drug resistance (Verma and Mehta, 2007; Iismaa et al., 2009; Shao et al., 2009; Seo et al., 2010) . A series of studies have shown that the induction of TGase 2 contributes to constitutive nuclear factor-kB (NF-kB) activation via polymerization of the inhibitor of NF-kB (Lee et al., 2004; Kim et al., 2006; Park et al., 2006) , and that this is one of the mechanisms of drug resistance in cancer cells (Mehta et al., 2004; Herman et al., 2006; Kim et al., 2006 Kim et al., , 2008 Kim et al., , 2009 Park et al., 2006; Gangadharan et al., 2009) . Increased TGase 2 expression correlates with increased NF-kB activity in breast cancer tissue ). Amplification of NF-kB-mediated signaling activity by TGase 2 appears to be mediated by the depletion of peroxisome proliferator-activated receptor-g, a known inhibitor of NF-kB (Maiuri et al., 2008) . Either case of TGase-2-mediated downregulation of inhibitor of NF-kB or peroxisome proliferator-activated receptor-g presents reducing suppressor of inflammatory transcription factors. We have proposed that TGase-2-mediated protein-protein crosslinking serves as a unique mechanism of secondary signaling through post-translational modification (Seo et al., 2010) .
The von Hippel-Lindau (VHL) tumor suppressor protein, as part of a ubiquitin-ligase complex, is well known to downregulate insulin-like growth factor-1 (IGF-1R; Yuen et al., 2007) . In renal cell carcinoma cells, VHL also downregulates NF-kB activity by suppressing NF-kB target anti-apoptotic genes such as FLICE inhibitory protein (c-FLIP), survivin, inhibitor of apoptosis-1 (IAP-1) and c-IAP-2, which sensitizes cells to tumor necrosis factor-induced cytotoxicity (Qi and Ohh, 2003) . Importantly, VHL has been shown to downregulate the hypoxia-inducible factor (HIF) by targeting HIF-1a subunit for polyubiquitinylation and proteasomal degradation, resulting in inhibit diverse growth factor involved in renal cyst formation and angiogenesis, such as transforming growth factor-a, vascular endothelial growth factor, platelet-derived growth-factor B chain and IGF-1 (Kaelin, 2002; Carroll and Ashcroft, 2006) . Although the mechanism of inhibition of NF-kB and IGF-1R by VHL are well documented, it is not fully understood how the loss of VHL induces the activation of NF-kB and the level of expression of IGF-1R. Also, in contrast to the regulation of VHL by deletion, mutation or promoter methylation of the VHL gene, which have been described (Curtis and Goggins, 2005; Tischoff and Tannapfel, 2008; Cowey and Rathmell, 2009) , the mechanisms of regulation of VHL at the protein level have yet to be elucidated. In this study, we investigated whether TGase 2 regulates VHL, thereby regulating IGF-1R stability and NF-kB activation during tumorigenesis.
Results

Inverse correlation between VHL and TGase 2
We examined the effect of TGase 2 gene knockdown in cells expressing IGF1-R-b. TGase 2 gene knockdown decreased the levels of endogenous IGF-1R-b protein in both NCI/ADR-RES and MDA-MB-231 cells ( Figure 1a ). We also have examined protein level of HIF-1a because HIF-1a is known as an actuator of IGF-1R-b (Figure 1b ). HIF-1a protein level was decreased by small-interfering RNA (siRNA) of TGase 2 treatment in NCI/ADR-RES and MDA-MB-231 cells. HIF-1a activity assay was performed using hypoxia transcriptional-response element-luciferase. Reporter assay showed hypoxia transcriptional-response element-luciferase activity was also about 15-and 24-fold decreased by siRNA of TGase 2 treatment to compare with the negative siRNA treatment in NCI/ADR-RES and MDA-MB-231 cells, respectively (Figure 1b, down) . We next used several different cell lines with high levels of TGase 2 expression (MDA-MB-231 drug-resistant and NCI/ADR-RES cell lines. IGF-1R-b levels was analyzed by immunoblot after TGase 2 inhibition by treatment with a TGase-2-specific siRNA (100 nM for 72 h). (b) After TGase 2 inhibition by treatment with a TGase-2-specific siRNA (100 nM for 72 h), levels of HIF-1a and hypoxia transcriptional-response element-luciferase activity were analyzed by western blotting and dual-luciferase reporter assay system, respectively. Bars represent means ± s.d. ***Po0.001 according to the Student ' s t-test. (c) Expression of endogenous VHL was decreased in NCI/ADR-RES ovarian cancer cells and MDA-MB-231 breast cancer cells compared with HEK293 and MCF7 cells. Cytosolic fractions of HEK293, MCF7, NCI/ADR-RES and MDA-MB-231 cells were subjected to immunoblot analysis using anti-TGase 2 and anti-VHL antibodies. (d) VHL was downregulated by TGase 2 at the post-transcriptional level but not the transcriptional level. HEK293 and MCF7 cells were transiently transfected with an expression vector for TGase 2 and then treated with cycloheximide at 10 mg/ml to prevent proteins synthesis. Western blotting analysis was carried out using anti-TGase 2 and anti-VHL antibodies (upper panel). HEK293 and MCF7 cells were transiently transfected with an expression vector for TGase 2 and VHL. Transcription levels of TGase 2 and VHL were analyzed by RT-PCR (middle panel) and determined by real-time PCR, quantified and normalized by glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene level (lower panel). (e) Expression of ectopic VHL and TGase 2 in HEK-293 and MCF7 cells. Cells were co-transfected with the indicated expression plasmids for 24 h, and then treated with or without CTM (0.5 mM) for 24 h. TGase 2 and VHL levels were analyzed by western blotting using anti-TGase 2 and anti-VHL antibodies. (f) Ectopically expressed VHL was downregulated by overexpression of ectopic TGase 2 in a dose-dependent manner. Cells were transiently co-transfected with an expression vector for HA-VHL and increasing amounts of an expression vector for TGase 2, and an expression vector for b-galactosidase was co-transfected in each experiment as a control for transfection efficiency. Cell extracts were prepared and analyzed by immunoblot using anti-TGase 2 and HA antibodies. breast cancer cells and NCI/ADR-RES drug-resistant ovarian cancer cells) or no expression of TGase 2 (MCF7 breast cancer cells) and human embryonic kidney cell line 293 (HEK293) immortalized kidney cells). The results of several recent studies from our laboratory have shown that increased TGase 2 expression has a key role in the acquisition of drug resistance by cancer cells (Lee et al., 2004; Herman et al., 2006; Kim et al., 2006 Kim et al., , 2008 Park et al., 2006) . The level of VHL in NCI/ADR-RES and MDA-MB-231 breast cancer cells was lower than in HEK-293 and MCF7 cells, and the level of endogenous VHL inversely correlated with TGase 2 in the cancer cell lines (Figure 1c ). To detect endogenous VHL depletion by TGase 2 transfection, cells were treated with cycloheximide. The depletion of endogenous VHL was dependent on protein modification rather than transcriptional regulation ( Figure 1d ). We have not observed any change of RNA level of VHL by reverse transcriptase-PCR (RT-PCR) and quantitative RT-PCR after TGase 2 transfection (Figure 1d ). To test the hypothesis, that TGase 2 transamidation is involved in cell after TGase 2 transfection, it would be critical to demonstrate that TGase 2 is active as a protein crosslinker inside the cell. Therefore, we performed the biotin-amido-pentylamineactive staining with or without TGase 2 transfection in MCF 7 cells. The cells with TGase 2 clearly showed increase of TGase 2 crosslinks (Supplementary Figure  S1) . We next tested whether the level of ectopic VHL inversely correlated with ectopic TGase 2, and further assessed the effect of TGase 2 inhibition using cystamine and catalytically inactive TGase 2 C277S in cell lines. Levels of ectopic VHL were reduced by co-expression of TGase 2, and this effect was abrogated by inhibition of TGase 2 using cystamine or expression of catalytically inactive TGase 2 C277S (Figure 1e) . Furthermore, the level of ectopic VHL was markedly decreased by TGase 2 in a dose-dependent manner (Figure 1f ). These results suggested that the crosslinking catalytic activity of TGase 2 is responsible for VHL depletion. expression is restored by inhibition of TGase 2. (a) Endogenous VHL expression was increased by TGase 2 knockdown in NCI/ADR-RES and MDA-MB-231 and cell lines. VHL level was analyzed by western blotting after TGase 2 inhibition by treatment with a TGase-2-specific siRNA (30 nM siRNA for 48 h). (b) Endogenous TGase 2 and VHL were bound together in cells. Cytosolic extracts (500 mg) were subjected to immunoprecipitation using an anti-VHL (1 mg) and anti-TGase 2 antibodies (1 mg). Immune complexes were analyzed by western blotting using anti-TGase 2 and anti-VHL antibodies. Normal mouse immunoglobulin G (IgG; 1 mg) served as a negative control. (c) Depletion of ectopic VHL is restored by inhibition of TGase 2 by treatment with CTM or a TGase-2-specific siRNA in NCI/ADR-RES and MDA-MB-231 cells. Cells were transfected with an HA-VHL plasmid with or without TGase-2-specific siRNA treatment for 48 h (right panel), or with or without CTM treatment for 24 h (left panel). (d) There was no protein level change after CTM treatment. Cells were transfected with an expression plasmid for HA-VHL with or without CTM treatment (0.5 mM) for 24 h, and then analyzed by western blotting using anti-TGase 2 and HA antibodies. (e) Expression of VHL was increased in cytosol by TGase 2 gene silencing in NCI/ADR-RES and MDA-MB-231 cancer cells. An HA-VHL expression plasmid was transfected into cells with or without a TGase-2-specific siRNA for 24 h. Cells were re-seeded on to two-chamber slides for 16 h. Cells were analyzed by immunocytochemistry using an anti-HA primary antibody and a fluorescence-conjugated anti-mouse immunoglobulin secondary antibody to detect HA-VHL. Cells were counterstained with 4,6-diamindino-2-phenylindole to visualize nuclei. Scale bar, 20 mm.
( Figure 2c) , we examined the effect of the inhibition of endogenous TGase 2 activity on VHL protein levels. NCI/ADR-RES and MDA-MB-231 cells, which contained high levels of TGase 2, were transiently transfected with a TGase-2-specific siRNA (Figure 2a ). Endogenous VHL was detected by western blotting after siRNA of TGase 2 treatment in NCI/ADR-RES and MDA-MB-231 cells (Figure 2a ). Endogenous VHL was clearly increased by siRNA of TGase 2 treatment. To test whether endogenous TGase 2 and VHL are bound together, we performed immunoprecipation (Figure 2b ). Western blotting of TGase 2 after immunoprecipation using VHL antibody with protein extracts from NCI/ADR-RES and MDA-MB-231 cells showed the endogenous TGase 2 band. Western blotting of VHL after immunoprecipation using TGase 2 antibody also showed endogenous VHL band ( Figure 2b ). We next examined the effect of the inhibition of endogenous TGase 2 on ectopic HA-VHL protein levels ( Figure 2c ). NCI/ADR-RES and MDA-MB-231 cells, which contained high levels of TGase 2, were transiently transfected with an expression vector for HA-VHL together with a TGase-2-specific siRNA or cystamine treatment. The levels of ectopic HA-VHL were increased in response to cystamine treatment or gene knockdown as compared with untreated control cells that expressed HA-VHL alone ( Figure 2c ). To exclude the possibility that cystamine (CTM) induced the expression of VHL, we repeated the experiment in HEK 293 and MCF 7 cells. There was no difference in the level of HA-VHL between control and CTM-treated groups, which indicated that CTM was not a direct inducer of VHL ( Figure 2d ). In addition, immunocytochemical staining of HA-VHL-alone-transfected NCI/ADR-RES and MDA-MB-231 cells using a monoclonal anti-HA antibody resulted in diminished expression of HA-VHL and VHL localized to the nucleus. By comparison, cells that were co-transfected with a TGase-2-specific siRNA resulted in enhanced expression of HA-VHL and VHL exhibited cytoplasmic and nuclear localization of HA-VHL ( Figure 2e ). This result indicates that TGase 2 appeared to preferentially target VHL in the cytosol, where TGase 2 is most abundant.
TGase 2 association with VHL and proteasome-dependent degradation of VHL polymer by TGase 2 To determine whether VHL polymers generated through TGase-2-catalyzed crosslinking were metabolically degraded, we tested three different proteolytic inhibitors (proteasomal, lysosomal and calpain inhibitors) for their ability to block VHL degradation. Depletion of VHL monomers by TGase 2 was abrogated by treatment with the proteasome inhibitor MG132, but not the calpain or lysosomal inhibitor (Figure 3a ). To determine whether TGase 2 directly interacted with VHL, cells were transiently co-transfected with expression vectors for HA-VHL and TGase 2, with or without MG132 treatment, and then subjected to immunoprecipitation using an anti-HA antibody followed by immunoblot analysis. TGase 2 was detected in VHL precipitates, and the amount of TGase 2 precipitates was increased with MG132 treatment (Figure 3b ). Reverse western blotting of VHL after immunoprecipation using TGase 2 antibody also showed VHL band and the amount of VHL precipitates was increased with MG132 treatment. These results suggested that VHL interacts with TGase 2, and that VHL complexes are specifically degraded via a proteasome-dependent mechanism. TGase 2-VHL polymers were readily detected, and the level of polymer increased on treatment of cells with MG132. To test whether ubiquitination may be involved in VHL polymer degradation, the same set of immunoprecipitates in Figure 3b were analyzed by immunoblot using an anti-ubiquitin antibody (Figure 3c ). TGase-2-mediated HA-VHL polymers appeared to be ubiquitinated and degraded via the proteasome.
Competition assay for VHL polymerization using synthetic peptides in vitro To test whether VHL is a substrate of TGase 2, purified recombinant human VHL was incubated with purified human TGase 2 in vitro. TGase 2 induced the polymerization of VHL in a dose-dependent manner ( Figure 4a ). The #1 and #3 arrowheads in Figure 4a denotes proteins identified by Malditof analysis as VHL and #2 denote chaperonin in the Table. To identify the crosslinking sites in VHL, we analyzed in-gel purified VHL monomers and polymers using mass spectroscopy (MS). Figure 4b shows the derived amino acid sequences of VHL monomer and polymer, with red-colored characters corresponding to residues identified by MS, and blue-colored characters (in the VHL polymer) corresponding to blocked residues after polymerization. The results indicated that glutamines 164 and 203 are involved in TGase-2-induced VHL polymerization (Figure 4b ). To determine whether VHL polymerization was due to TGase 2 crosslinking activity, VHL was incubated with the inactive TGase 2 C/S mutant ( Figure 4c ). Inactive TGase 2 C/S did not interact with or polymerize VHL. To more rigorously define TGase 2 target sequences, we obtained the TGase 2 target candidate sequences in Figure 4b , and used them in a competition assay in which synthetic peptides were used to compete with full-length VHL in the TGase-2-mediated polymerization reaction ( Supplementary Figure S2 ). For the in vitro crosslinking reactions, each peptide containing candidate glutamine residues (V-1, V-2, V-5 or V-6) and a mixture of V-3 and V-4, which contained random lysine residues were used. The reaction mixture of purified VHL and TGase 2 was incubated with or without each of the indicated peptides (2 nmol). After 10 min at 37 1C, the reactants were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and visualized by Coomassie staining (Supplementary Figure S2) . Among the candidate peptides, V2 exhibited the most effective recovery from VHL depletion by TGase 2 crosslinking (Supplementary Figure S2a ). Mutant Q203G of VHL showed less efficiency to make VHL polymers in vitro (Supplementary Figure S2b ). However, TGase 2 depleted mutant Q203G with almost the same efficiency as it did with wild VHL in HEK293 cells (Supplementary Figure S2c) .
We identified one glutamine site of TGase-2-target sites in VHL, but we could not identify TGase 2 targeting lysine residue of VHL. Therefore, it is possible that TGase 2 can make crosslink efficiently between lysine residue of VHL and glutamine residue of other proteins in cells although glutamine residue of VHL is blocked. Mapping the functional lysine residue remains to be elucidated.
Restoration of VHL expression by TGase inhibition results in the suppression of NF-kB activity NF-kB activity has been shown to be downregulated by VHL (Jung et al., 2003; Qi and Ohh, 2003) . NF-kB activity in HA-VHL-expressing cells treated with a TGase-2-specific siRNA or the TGase 2 inhibitor CTM was lower than in untreated cells that expressed HA-VHL alone (Figure 5a) . We also performed an electrophoretic mobility shift assay to assess NF-kB DNA binding activity. Expression of ectopic VHL alone or in combination with TGase 2 inhibition decreased NF-kB DNA binding activity (Figure 5b ). Apoptosis was more efficiently induced in HA-VHL-expressing cells that were also transfected with a TGase-2-specific siRNA as compared with cells that were transfected with HA-VHL alone, based on annexin-V-positive staining and relative levels of cleaved caspase-3 and PARP (Figure 5c ). Previous reports have indicated that VHL inhibits the expression of IGF-1R (Yuen et al., 2007) . TGase 2 inhibition by CTM or gene knockdown resulted in the stabilization of ectopic VHL, and this correlated with decreased IGF-1R levels in drug-resistant cancer cell lines (Figure 5d ). These results indicated that downregulation of VHL by TGase 2 is essential for IGF-1R protein expression.
Downregulation of VHL in TGase-2-transgenic mice
To evaluate the relationship between VHL and TGase 2 in vivo, we generated TGase-2-transgenic mice carrying a mouse TGase 2 transgene . As VHL has been well studied in kidney, we investigated the level of VHL in the kidneys of TGase-2-transgenic mice. The kidneys of TGase-2-transgenic mice did not exhibit any histological abnormalities and were normal in overall gross appearance. Analysis of VHL protein levels in the kidneys of three different wild-type and TGase-2-transgenic mice by immunoblot showed that VHL levels leupeptin, lysosome inhibitor, 50 mM; MG132, proteasome inhibitor, 5 mM) for 12 h after co-transfection. TGase 2 and VHL levels were analyzed by western blotting using anti-TGase 2 and anti-HA antibodies, respectively. (b) Proteasome inhibition caused an increase in interaction between VHL and TGase 2. Cells were co-transfected with HA-VHL and TGase 2 for 36 h and then treated with MG132 (10 mM) for 6 h. Cytosolic extracts (500 mg) were subjected to immunoprecipitation using an anti-HA (recognized HA-VHL) and antiTGase 2 antibodies. Immune complexes were analyzed by western blotting using anti-TGase 2 and anti-HA antibodies. TGase 2 and VHL formed a stable complex in a proteasome inhibition-dependent manner. Normal mouse immunoglobulin G (IgG) served as a negative control. (c) TGase 2-VHL complexes were degraded in ubiquitin-proteasome-dependent manner. Cytosolic fractions (prepared as described above) subjected to immunoprecipitation using an anti-HA antibody. Immune complexes were analyzed by western blotting anti-ubiquitin antibody.
were lower in TGase-2-transgenic mice than in wild-type mice (Figure 6c ). To determine whether VHL depletion due to overexpression of TGase-2-influenced IGF-1R protein levels, we analyzed kidney samples from wildtype and TGase-2-transgenic mice by immunoblot using an anti-IGF-1R antibody. IGF-1R protein levels were higher in TGase-2-transgenic mice than in wild-type mice, as expected (Figure 6c ). We also evaluated whether TGase 2 altered the expression of VHL and IGF-1Rb by immunohistochemistry. Decreased levels of VHL and increased levels of IGF-1R were detected in TGase 2 transgenic mice (Figure 6d ). In addition, the expression of HIF-1a and erythropoietin (EPO) EPO were increased in TGase-2-transgenic mice. EPO is the primary humoral regulator of mammalian erythropoiesis resulting in an increased blood oxygen-carrying capacity. EPO RNA levels increase several hundred fold in rodent liver and kidney in response to hypoxia (Wang and Semenza, 1993) . Analysis of NF-kB DNA binding activity by electrophoretic mobility shift assay revealed that NF-kB activity was increased in TGase-2-transgenic mice as compared with wild-type mice (Figure 6e ).
Thus, VHL levels were decreased in the kidneys of TGase-2-transgenic mice as compared with wild-type mice, and this correlated with higher levels of IGF-1R. These results suggested that TGase 2 inhibits VHL, which in turn induces NF-kB activation and expression of IGF-1R in vivo.
Discussion
Here we demonstrated that TGase 2 is a critical regulator of VHL during tumorigenesis and contributes to the NF-kB activation and stability of IGF-1R, HIF-1a and EPO through VHL depletion. The results of the current study reveal a novel regulatory mechanism of tumor suppression by TGase 2 that is independent of other well-characterized regulatory mechanisms in tumor cells, such as genetic mutation and epigenetic modification (Figure 6f ). TGase 2 can polymerize VHL, which results directly in the depletion of VHL through ubiquitination and proteasomal degradation (Figure 3) . We demonstrated that VHL can be polymerized in vitro, Figure 4 VHL forms a homopolymer through TGase 2-mediated crosslinking. (a) TGase 2 induced the polymerization of VHL in a dose-dependent manner in vitro. Purified recombinant VHL was polymerized in vitro by purified recombinant human TGase 2. VHL polymers were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and either visualized by Coomassie Blue staining (left panel), or analyzed by western blotting using anti-VHL and anti-TGase 2 antibodies (right panel). Shown is the mass analysis of released peptides following proteolytic digestion of putative VHL monomers (arrowhead #1) and polymers (arrowhead #3). Arrowhead #1B indicates the 60 kDa chaperonin that may strongly interact with VHL during the purification process. (b) The difference between mass recoveries from monomers and polymers is marked in blue. (c) TGase 2 crosslinking activity is important for VHL polymerization. Purified human recombinant TGase 2 and TGase 2-C/S were incubated with purified recombinant VHL. Samples were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and visualized by Coomassie Blue staining. CI, confidence interval. and VHL depletion can be reversed by an inactive TGase 2 C/S mutant. Although we did not identify the VHL binding partner, our results suggest that TGase 2 lysine residues could serve as acyl donors.
IGF-1R is a key mediator of tumor cell survival and is overexpressed in many cancers (Casa et al., 2008; Yuen et al., 2009) . IGF-1R is downregulated by VHL in an HIF-1a-independent manner (Yuen et al., 2009) . VHL decreases IGF-1R transcription and mRNA stability, resulting in the inhibition of renal tumorigenesis and chemosensitivity in renal cell carcinoma (Yuen et al., 2007) . Thus, as a negative regulator, VHL represents an attractive therapeutic target. The results of previous studies have indicated that VHL functions primarily in oxygen-sensing pathways. In addition, VHL has been linked to several diseases, such as heamangioblastoma, renal cell carcinoma and phaeochromocytoma (Kaelin, 2002) . Although the role of VHL in tumorigenesis has been well documented, the mechanism of negative regulation of VHL remains to be elucidated. The identification of VHL-negative regulators and elucidation of their mechanism of action is essential to our understanding of VHL-related tumorigenesis. In addition to hypoxia, biallelic inactivation of VHL, as well as Figure 5 Expression of ectopic VHL in combination with the inhibition of TGase 2 suppresses NF-kB activity and decreases IGF-1R-b levels. (a) NF-kB activity was reduced by ectopic expression of VHL and inhibition of TGase 2. Cells were co-transfected with HA-VHL and pNF-secreted alkaline phosphatase (SEAP) for 24 h and then treated with or without CTM (0.5 mM) for 24 h (right panel) Alternatively, cells were transfected with a TGase-2-specific siRNA using reverse transfection for 24 h, and the indicated expression plasmids for 48 h (right panel). After incubation, culture medium was collected and NF-kB transcriptional activity was assessed using the SEAP reporter assay. Bars represent means±s.d. *Po0.05; **Po0.01; ***Po0.001 according to the Student ' s t-test. (b) Nuclear extracts (10 mg) of the cells described in (a) were prepared and analyzed by an electrophoretic mobility shift assay using a 32 P-labeled NF-kB probe. (c) Analysis of apoptosis by annexin V/propidium iodide staining and western blotting analysis of cleaved caspase 3 and PARP. Cells were transfected with an expression plasmid for VHL and a TGase-2-specific siRNA. Annexin V/PI staining was assessed by flow cytometry. The percentage of gated cells in quadrants corresponding to early and late apoptosis are shown (upper panel). Whole-cell extracts were prepared and analyzed by immunoblot using anti-cleaved caspase-3, anti-PARP and anti-b-actin antibodies. (d) Inhibition of TGase 2 restored VHL protein levels and resulted in the downregulation of endogenous IGF-1R-b protein levels. Cells were transfected with the indicated plasmids for 24 h and then treated with or without CTM (0.5 mM) for 24 h before harvesting (left panel). Alternatively, cells were transfected with a TGase-2-specific siRNA using reverse transfection for 24 h, and the indicated expression plasmids for 24 h (right panel). Whole-cell extracts were analyzed by western blotting using anti-TGase 2, anti-IGF-1R-b and anti-VHL antibodies. mutation, deletion and promoter methylation of the VHL gene, induce the translocation of HIF-1a from the cytoplasm to the nucleus where it is transcriptionally active (Otrock et al., 2009) . The current results suggest a new paradigm of potentiation of cancer progression, involving depletion of tumor suppressors by TGase-2-induced crosslinking and proteasomal degradation, which is independent of other known signaling mechanisms. This may well be possible that in the same conditions TGase 2 could contribute to activation of the NF-kB cascade via VHL depletion. As VHL has a clear role in the degradation of HIF-1a, increased expression of TGase 2 via HIF-1a binding to its promoter would result into VHL depletion, thus raising the stability of HIF-1a and further increasing TGase 2 transcription in a positive activation loop (Jang et al, 2010) .
Gene silencing of TGase 2 resulted in increased VHL stability, whereas overexpression of TGase 2 decreased the levels of VHL protein in cells, and TGase-2-mediated inhibition of VHL-induced NF-kB activation. This pathway may have a key role in the acquisition of drug resistance by cancer cells and cancer progression. TGase-2-mediated VHL depletion increases the levels of IGF-1R, a known actuator of Akt-and mitogen-activated protein kinase signaling pathways that stabilize HIF-1a and HIF-2a and upregulate vascular endothelial growth factor in renal cell carcinoma (Yuen et al., 2009) and EPO, a known the primary humoral regulator of mammalian erythropoiesis resulting in an increased blood oxygen-carrying capacity (Wang and Semenza, 1993) . The results of this study provide compelling support for TGase 2 as a viable therapeutic target for a novel approach to cancer treatment.
Materials and methods
Antibodies and reagents
The anti-VHL and HIF-1a antibodies were purchased from BD Pharmingen (San Diego, CA, USA), the anti-TGase 2 antibody from NeoMarkers (clone CUB 7402; Fremont, CA, USA), the anti-b-actin from Abcam (Cambridge, UK), the anti-IGF-1R-b, anti-HA-probe (F-7), normal mouse immunoglobulin G antibodies from Santa Cruz Biotechnology (Santa Cruz, CA, USA), and the anti-PARP and anti-cleaved caspase-3 (Asp175) antibodies from Cell Signaling Technologies (Beverly, MA, USA). We obtained Lipofectamine 2000, Lipofectamine RNAiMAX transfection regents and negative control siRNA Figure 6 Overexpression of TGase 2 leads to the decrease level of VHL and the increase level of IGF-1Rb, HIF-1a and EPO, thereby enhances the NF-kB activation in vivo. (a) After perfusion, frozen tissues from wild-type and TGase-2-transgenic mice were homogenized, and then TGase 2, VHL and IGF-1R-b levels were detected by western blottingt analysis using anti-TGase 2, anti-VHL and anti-IGF-1R-b antibodies, respectively. (b) Immunohistochemical analysis of TGase 2, VHL, IGF-1Rb, HIF-1a and EPO in the kidneys of TGase-2-transgenic and wild-type mice showed an inverse relationship between TGase 2 and VHL ( Â 100). Scale bar, 100 mm. (c) Tissues were prepared as described in above, and then nuclear extracts were analyzed by an electrophoretic mobility shift assay using a 32 P-labeled NF-kB probe. A competition assay using unlabeled probe was performed to exclude the possibility of nonspecific binding (data not shown). (d) Proposed model for the role of VHL and TGase 2 in NF-kB activation. TGase 2 induces and extends NF-kB activity through the depletion of I-kBa and VHL via polymerization and proteasomal degradation. I-kBa is a known major inhibitor of NF-kB; VHL is a tumor suppressor that regulates IGF-1R and HIF-1a. Depletion of I-kBa and VHL promotes survival, growth, migration, drug resistance and resistance to apoptosis of cancer cells.
from Invitrogen Life Technologies (Carlsbad, CA, USA). Calpeptin and MG132 were obtained from Calbiochem (San Diego, CA, USA), and leupeptin and CelLytic NuCLEAR Extraction Kit were obtained from Sigma-Aldrich (St Louis, MO, USA). Fluorescein isothiocyanate (FITC)-conjugated antimouse immunoglobulin (Jackson Immuno Research Labs Co., West Grove, PA, USA) was obtained commercially and streptavidin Alexa Flour 546 conjugated was obtained from Invitrogen Life Technologies. Lightcycler 480 SYBR Green I Master was obtained from Roche (Mannheim, Germany). Superscript III First-Strand synthesis system for RT-PCR and TRIzol were obtained from Invitrogen Life Technologies. Protein A/G-agarose beads was purchased from Pierce (Rockford, IL, USA). pCR3-HA-VHL clone was kindly provided by Dr HongDuk Youn (Seoul National University, College of Medicine).
Cell culture
Human embryonic kidney cell lines HEK-293, human breast cancer cell lines including MCF7, MDA-MB-231 and the human ovarian adenocarcinoma cell line NCI/ADR-RES were obtained from American Type Culture Collection (Rockville, MD, USA). Cells were grown in RPMI or Dulbecco's modied Eagle's medium supplemented with 10% fetal bovine serum (Hyclone, Logan, UT, USA), 1 mM sodium pyruvate, 10 mm 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid and 100 U/ml penicillin-streptomycin (Gibco-BRL, Grand Island, NY, USA) and maintained in a humidified atmosphere of 5% CO 2 at 37 1C.
Immunocytochemistry HA-VHL was visualized by immunocytochemistry and confocal microscopy. Cells were seeded in two-well slide chambers As negative controls, cells were incubated with Lipofectamine RNAiMAX and a universal negative siRNA (Invitrogen Life (1 Â 10 5 cells/well) with TGase-2-specific siRNA or universal negative siRNA at 1 day before transfection. Cells were transfected with mock vector or HA-VHL for 24 h, after which cells were washed with phosphate-buffered saline (PBS), incubated in cold 3.7% paraformaldehyde for 15 min and then washed with 0.1% PBS-Tween 20 (PBS-T). Cells were permeabilized for 5 min using 0.5% PBS-T, washed again in 0.1% PBS-T, incubated for 1 h in 10% calf serum in PBS containing 0.5% gelatin and then washed with 0.1% PBS-T. Fixed cells were incubated at room temperature with mouse monoclonal anti-HA probe for 2 h, washed with 0.1% PBS-T and then incubated with fluorescent isothiocynate-conjugated anti-mouse immunoglobulin G (1:200 dilution, Jackson Immuno Research Co.) for 1 h. Cells were washed with 0.1% PBS-T, incubated at room temperature with 4,6-diamindino-2-phenylindole nuclear dye (Sigma-Aldrich Co.) for 5 min, washed with 0.1% PBS-T again and then treated with VectaShield. Cells were visualized using a Zeiss axiovert LSM510 microscope (Zeiss, Feldbach, Switzerland).
TGase 2 silencing by treatment with a siRNA A siRNA duplex targeting human TGase 2 (5 0 -AAGAGCGA GAUGAUCUGGAACTT-3 0 ) was introduced into cells using Lipofectamine RNAiMAX (Invitrogen Life Technologies) according to the manufacturer's instructions. Cells were harvested at 72 h post transfection, and then cytosolic fractions or whole-cell extracts were prepared for immunoblot analysis. As negative controls, cells were incubated with Lipofectamine RNAiMAX and a universal negative siRNA (Invitrogen Life Technologies).
Purification of human VHL, TGase 2 wild-type and TGase 2 mutant (C277S)
The human VHL complementary DNA was subcloned into modified pET32 (Novagen, Madison, WI, USA) using BamHI/ XhoI restriction enzymes, which resulted in the addition of a 23-residue polyhistidine tag (MHHHHHHGSLVPRSEN-LYFQGS, 6 Â His) to the amino terminus and a 10 residue polyhistidine tag (LEHHHHHHHH, 8 Â His) to the carboxyterminus of VHL. The human TGase 2 wild type and C277S mutant were purified using reported methods. Recombinant VHL was overexpressed in Escherichia coli strain Rosetta 2 (DE3). Cells were grown at 37 1C in Terrific Broth (SigmaAldrich Co.) to an OD 600 (optical density 600) of 0.7, and then the expression of recombinant protein was induced by adding 0.1 mM isopropyl b-D-thiogalactopyranoside. Cells were allowed to continue growing at 37 1C for 5 h following isopropyl b-D-thiogalactopyranoside induction, after which cells were harvested by centrifugation. The cell pellet was resuspended in ice-cold lysis buffer (25 mM Tris-HCl, pH 7.4, 138 mM NaCl, 2 mM KCl, 10% (v/v) glycerol, 1% (v/v) TritonX-100, 1 mM phenylmethylsulfonyl fluoride, 10 mg of lysozyme) and then stored at À80 1C. All protein purification steps were performed under ice-cold conditions. Frozen cells were rapidly thawed and then homogenized by sonication. The crude lysate was subjected to centrifugation at 36 000 Â g for 1 h at 4 1C and the resultant supernatant was applied to a Ni-nitriloacetic acid column. The column was washed with wash buffer (60 mM imidazole, 500 mM NaCl, 20 mM Tris-HCl, pH 7.9, 10% (v/v) glycerol) and protein was eluted with elution buffer (500 mM imidazole, 500 mM NaCl, 20 mM Tris-HCl, pH 7.9, 10% (v/v) glycerol). Eluted protein was concentrated and applied to a Superdex 75 10/300 GL column (GE Healthcare, Piscataway, NJ, USA) in buffer consisting of 100 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA and 5 mM dithiothreitol.
Polymerization of VHL by TGase 2 and M/S (mass spectrometer) analysis Purified guinea pig TGase 2 (Sigma-Aldrich Co.) was activated with reaction buffer (100 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 10 mM CaCl 2 , 5 mM dithiothreitol). Activated TGase 2 was incubated in 40 ml of reaction buffer (100 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 20 mM CaCl 2 ) with human VHL at 37 1C for 2 h. The reaction mixture was separated using 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and the high-molecular weight proteins, the intact VHL protein band at the top of the gel, or the band at 25 kDa were excised, destained and dried in a SpeedVac evaporator (Savant, Farmingdale, NY, USA). Dried gel pieces were re-swollen with 30 ml of 25mM sodium bicarbonate containing 50 ng of trypsin (Promega, Madison, WI, USA) at 37 1C overnight. Samples were desalted using Zip-Tips C18 (Millipore, Bedford, MA, USA). a-Cyano-4-hydroxy-cinnamic acid (10 mg; AB SCIEX, Foster City, CA, USA) was dissolved in 1 ml of 50% acetonitrile in 0.1% trifluoroacetic acid (TFA) and then 1 ml of the matrix solution was mixed with an equivalent volume of sample. Analysis was performed using a 4700 Proteomics Analyzer TOF/TOF system (AB SCIEX). The TOF/TOF system was operated in positive ion reflect mode. Mass spectra were first calibrated in the closed external mode using the 4700 proteomics analyzer calibration mixture and analyzed with GPS Explorer software, version 3.5 (AB SCIEX). The MS/MS spectra acquired were searched against the Swiss-Prot and NCBI databases using an in-house version of MASCOT. The mass spectrometry was set for electrospray ionization (ESI) in positive mode. A syringe pump was used to introduce the calibration solution for automatic tuning and calibration of the linear ion trap (LTQ) in ESI-positive-ion mode. Infusion of the digested sample (trypsin) into the ionization source of the mass spectrometer was accomplished with liquid chromatographic separation. The following settings were used: spray voltage was set at þ 1.1 kV; temperature of the capillary was set at 200 1C; capillary voltage was set at þ 20 V; and tube lens voltage was set at þ 100 V. The auxiliary gas was set to zero. Full scan experiments were performed to linear trap in the range m/z 150-2000. Systematic MS/MS experiments were carried out by changing the relative collision energy and monitoring the intensities of the fragment ions. The retrieved data resulted in different mass coverage between monomeric and polymeric forms of VHL. The blue-colored VHL sequence appears to be TGase 2 target sequences, such as LQVVR and LTQER.
Competition assay for VHL polymerization using synthetic peptides in vitro To characterize the TGase 2 target sequence in more detail, we obtained the TGase 2 target candidate sequences in Figure 4b and used them in a competition assay with synthetic peptides. Synthetic peptides were obtained by solid-phase synthesis and purified to >95% purity by preparative high-performance liquid chromatography (AnyGen Co., Gwanju, Korea). Peptides (listed in Figure 4d ) were dissolved in double distilled water. For the in vitro crosslinking reaction, each peptide containing a candidate glutamine residue (V-1, V-2, V-5 or V-6, 5 pmol) and the mixture of V-3 and V-4, which contained random lysine residues, were used (sequences are denoted in Figure 4d ). Purified VHL was incubated with 0.5 mU of TGase 2 in a reaction mixture containing 50 mM Tris, pH 7.5, 10 mM CaCl 2 , with or without each of the indicated peptides (2 nmol). After 10 min at 37 1C, the reactants were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and visualized by Coomassie staining.
Immunoblotting
Immunoblot analysis was performed according to standard established methods .
Immunoprecipitation
For immunoprecipitation assay, cytosolic fractions were prepared using CelLytic NuCLEAR Extraction Kit (SigmaAldrich Co.). Cytosolic fraction was mixed with normal mouse immunoglobulin G and A/G-agrose bead and incubated at 4 1C on a rotator for at 2 h. After incubation, centrifuged 14 000 r.p.m. for 10 min at 4 1C and then supernatant was mixed with binding buffer (50 mM Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1% NP40) supplemented with a protease and phosphatase inhibitor cocktail (Sigma-Aldrich Co.). Mixture was incubated overnight at 4 1C with antibodies (1 g). A/Gagarose beads (Pierce) were then added and incubated for 3 h at 4 1C, after which the beads were washed six times with binding buffer. Immune complex was released from beads by boiling in sample buffer, and then analyzed by western blotting using the antibodies indicated. Normal mouse immunoglobulin G antibody was used as a negative control.
Electrophoretic mobility shift assay
The NF-kB double-stranded oligonucleotide (5 0 -AGTTGA GGGGACTTTCCCAGG C-3 0 ) was purchased from Santa Cruz Biotechnology. It was labeled with the Reductive adenosine 5-[g-32 P]triphosphate triethylammonium salt (Amersham, Buckinghamshire, UK, AA0068, 9.25 MBq, 250 mCi, 10 mCi/ml per 25 ml) using T4 polynucleotide kinase (Takara, Kyoto, Japan) and then purified with MicroSpin G-25 columns (Amersham, , according to the manufacturer's instructions. Nuclear extract (10 mg) was incubated with binding buffer (10 mM Tris, 5% glycerol, 50 mM NaCl, 1 mM dithiothreitol, 1 nM EDTA) and 32 P-labeled NF-kB probe for 30 min at 37 1C and then DNA-protein complexes were resolved on a 6% non-denaturing polyacrylamide gel at 100 V in 0.5 Â TBE buffer (0.89 M Tris, 0.89 M boric acid, and 20 mM EDTA). The gel was exposed to a BAS-MS2040 plate (Fujifilm, Kanagawa, Japan) for 30 min in the BAS Cassette2 (Fujifilm), and signals were detected using a BAS-2500 Phosphor Imager (Fujifilm).
Apoptosis assay
Analysis of apoptosis by annexin V binding was carried out using an Annexin V-FITC Apoptosis Detection Kit (BD Biosciences, Mountain View, CA, USA), according to the manufacturer's instructions.
Immunohistochemistry
Immunohistochemical staining of mouse kidney tissue sections was performed using a vector ABC kit containing a biotinconjugated rabbit anti-mouse secondary antibody and avidine biotin complex solution, with DAB plus Chromogen (Lab Vison Co., Fremont, CA, USA). Tissue sections were deparaffinized with xylene and subjected to heat-induced antigen retrieval with 10 mM Tris, pH 9.0 and 1 mM EDTA for 20 min, followed by cooling at room temperature. Sections were fixed in 95% ethanol for 10 min, given a flow-through wash with water, blocked in hydrogen peroxide and Ultra V block (Lab Vison Co.) for 15 min each, and then incubated with primary antibody diluted in 20% mouse-on-mouse blocking solution/Tris-buffered saline and Tween 20 for 1 h at room temperature. Sections were washed three times in Trisbuffered saline and Tween 20, and treated with avidin biotin complex solution and horseradish peroxidase polymer for 30 min each, followed by washing three times in Tris-buffered saline and Tween 20. After this, the slides were incubated with DAB chromogen. Counterstaining was carried out with Mayer's Hematoxylin (Sigma-Aldrich Co.).
Generation of TGase-2-transgenic mice TGase-2-transgenic mice was generated as previously described .
Statistics
The results were presented as mean ± s.d. The Student's unpaired t-test was used for statistical evaluation. A P-value of 0.05, 0.01 or 0.001 was considered statistically significant.
In situ TGase 2 activity in cells TGase 2 enzyme activity in TGase-2-transfected cells was detected by labeling cells with 0.2 mM 5 0 -(biotinamido) pentylamine for 24 h (Jang et al., 2010) . After labeling, the 5 0 -(biotinamido) pentylamine-incorporated cellular proteins was analyzed by cytochemistry using streptavidin Alexa Flour 546 conjugated (Invitrogen Life Technologies, 1:500 dilution).
Dual-luciferase reporter assay
The promoter regions (5 0 -CCACAGTGCATACGTGGGCTC CAACAGGTCCTCTT-3 0 Â 5) of HIF-1a gene was subcloned into pGL3 basic vector. For measurement of HIF transcriptional activity reporter, cells were transfected with TGase-2-specific and negative siRNA through reverse transfection methods. After 48 h, cells were transiently co-transfected with pGL3-hypoxia transcriptional-response element (1 mg) and pRL3-SV40 (0.1 mg) for 24 h, then firefly and Renilla luciferase activities were measured using a dual luciferase assay kit (Promega).
RT-PCR and real-time PCR for TGase 2 and VHL For RT-PCR analysis, RNA was extracted using TRIzol reagent (Invitrogen Life Technologies) and complementary DNA was prepared with a SuperScript III First-Strand synthesis system (Invitrogen Life Technologies) according to the manufacturer's instructions. The TGase 2 primers were forward (5 0 -ACGATGCGCCCTTTGTCTTT-3 0 ) and reverse (5 0 -TTTGTTCAGGTGGTTCGCCCTT-3 0 ). The VHL primers were forward (5 0 -GCGTCGTGCTGCCCGTATG-3 0 ) and reverse (5 0 -TTCTGCACATTTGGGTGGTCTTC-3 0 ). Human TGase 2 and VHL mRNA expression were quantified using the Lightcycler 480 SYBR Green I Master kit (Roche) and their relative expression was determined by normalizing the expression of each target to glyceraldehyde 3-phosphate dehydrogenase. Amplification was conducted in a total volume of 10 ml for 40 cycles of 30 s at 95 1C, 30 s at 56 1C and 30 s at 72 1C. Samples were run in triplicate.
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